Skip to Content
Merck
  • Treatment of hypertension by increasing impaired endothelial TRPV4-KCa2.3 interaction.

Treatment of hypertension by increasing impaired endothelial TRPV4-KCa2.3 interaction.

EMBO molecular medicine (2017-09-14)
Dongxu He, Qiongxi Pan, Zhen Chen, Chunyuan Sun, Peng Zhang, Aiqin Mao, Yaodan Zhu, Hongjuan Li, Chunxiao Lu, Mingxu Xie, Yin Zhou, Daoming Shen, Chunlei Tang, Zhenyu Yang, Jian Jin, Xiaoqiang Yao, Bernd Nilius, Xin Ma
PMID28899928
ABSTRACT

The currently available antihypertensive agents have undesirable adverse effects due to systemically altering target activity including receptors, channels, and enzymes. These effects, such as loss of potassium ions induced by diuretics, bronchospasm by beta-blockers, constipation by Ca